文献速递白血病

急性髓系白血病的整合基因组-代谢分类定义了NPM1与黏连蛋白/DNA损伤突变亚组

Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations.
PubMed 文献 · Leukemia · 2021-06-30

该研究基于血清和尿液代谢组学对急性髓系白血病(AML)患者进行代谢分型,并结合基因组图谱。细胞内代谢组区分出三个AML簇,分别与NPM1突变、染色质/剪接体突变和TP53突变/非整倍体相关。整合分析进一步将NPM1突变AML分为两个亚组,其中NPM1/黏连蛋白突变亚组具有独特代谢特征和潜在治疗弱点。

要点

  • 血清与尿液代谢组学联合可改善AML的代谢特征描述。
  • 细胞内代谢组区分三个AML簇,与NPM1突变、染色质/剪接体突变和TP53突变/非整倍体相关。
  • NPM1/黏连蛋白突变亚组血清胆碱+氧化三甲胺和亮氨酸升高,突变负荷更高,炎症状态转录特征降低。

核心结论

  • 整合基因组-代谢分类可识别NPM1突变AML中富集黏连蛋白/DNA损伤基因突变的亚组,该亚组具有独特代谢和转录特征及潜在治疗脆弱性。

研究设计与样本

  • 研究对AML患者进行血清和尿液代谢组学分析,并结合细胞内代谢组学和基因组图谱进行整合分类。

主要发现

  • 细胞内代谢组区分三个AML簇,分别与NPM1突变、染色质/剪接体突变和TP53突变/非整倍体AML相关,并经生物体液分析确认。
  • 整合基因组-代谢谱定义两个NPM1突变AML亚组,其中NPM1/黏连蛋白突变亚组血清胆碱+氧化三甲胺和亮氨酸升高,突变负荷更高,炎症状态转录特征降低,对EGFR和MET抑制的离体反应更好。
  • 基于酶编码基因转录差异的计算机建模预测NPM1/黏连蛋白突变AML中NAD和嘌呤代谢改变,提示潜在脆弱性。

临床怎么用

  • 血清和尿液代谢组学联合可用于改善AML的代谢分型。
  • NPM1/黏连蛋白突变亚组的代谢特征可能为靶向治疗提供线索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although targeting of cell metabolism is a promising therapeutic strategy in acute myeloid leukemia (AML), metabolic dependencies are largely unexplored. We aimed to classify AML patients based on their metabolic landscape and map connections between metabolic and genomic profiles. Combined serum and urine metabolomics improved AML characterization compared with individual biofluid analysis. At intracellular level, AML displayed dysregulated amino acid, nucleotide, lipid, and bioenergetic metabolism. The integration of intracellular and biofluid metabolomics provided a map of alterations in the metabolism of polyamine, purine, keton bodies and polyunsaturated fatty acids and tricarboxylic acid cycle. The intracellular metabolome distinguished three AML clusters, correlating with distinct genomic profiles: NPM1-mutated(mut), chromatin/spliceosome-mut and TP53-mut/aneuploid AML that were confirmed by biofluid analysis. Interestingly, integrated genomic-metabolic profiles defined two subgroups of NPM1-mut AML. One was enriched for mutations in cohesin/DNA damage-related genes (NPM1/cohesin-mut AML) and showed increased serum choline + trimethylamine-N-oxide and leucine, higher mutation load, transcriptomic signatures of reduced inflammatory status and better ex-vivo response to EGFR and MET inhibition. The transcriptional differences of enzyme-encoding genes between NPM1/cohesin-mut and NPM1-mut allowed in silico modeling of intracellular metabolic perturbations. This approach predicted alterations in NAD and purine metabolism in NPM1/cohesin-mut AML that suggest potential vulnerabilities, worthy of being therapeutically explored.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Simonetti G, Mengucci C, Padella A, et al. Integrated genomic-metabolic classification of acute myeloid leukemia defines a subgroup with NPM1 and cohesin/DNA damage mutations. Leukemia. 2021. PMID: 34193978. doi:10.1038/s41375-021-01318-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。